
EPRX Stock Forecast & Price Target
EPRX Analyst Ratings
Bulls say
Eupraxia Pharmaceuticals is poised for success with its EP-104GI, as it targets a significant unmet medical need for EoE and esophageal strictures. Its Diffusphere technology sets it apart from existing steroids, providing improved efficacy, durability, and reduced treatment burden. While risks exist, the company's current market cap suggests a high probability of success, making it an attractive investment opportunity. As of 2036, based on an 11.0% WACC and 12.0x exit multiple, the net present value of EP-104GI is ~$500M, with an 85% probability of success factored in.
Bears say
Eupraxia Pharmaceuticals is facing significant challenges in terms of gaining widespread adoption and generating profits for its EP-104GI drug due to the differing endpoints in benign strictures when compared to its current EoE program. Additionally, the use of EP-104GI in strictures would likely require far fewer injections and possibly lower pricing, posing a risk to the company's revenue potential. While the data on EP-104GI's efficacy and safety look promising, the success of the upcoming randomized Phase 2b readout will be crucial in determining the drug's long-term viability and market potential.
This aggregate rating is based on analysts' research of Eupraxia Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
EPRX Analyst Forecast & Price Prediction
Start investing in EPRX
Order type
Buy in
Order amount
Est. shares
0 shares